The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Worth pointing out no algorthym transactions all o = ordinary. A good sign. This is still remarkably unknown
Wonder if it is Cannachord
Don't dispute it may be institution but purchased registered 9.47 am. Early but not crack of dawn.
Look at the timing Bruce. NOT a private investor I believe because held up til close!
£190K a lot for a private investor
....and no reason to panic. I reckon co will do a share split when SP is between £80 and £100!
Very odd that thre are no up to date broker ratings. This is well below the radar, - nice for us. It is an absolute steal. DYOR
...since April 2015 when the the stock price was £8. Rating does discount some good news, but the real key medium-term is the success of Siemen's high sensitivityTroponin cardiac test. I'm happy to keep running with this highly cash generative stock for now, but if it hit £45 in the first half of this year, I'de look to reduce.
Just taken a small position in this very interesting company with a partial monopoly.
....for what its worth, is that this is a very special situation which could result in a massive increase in SP if all goes according to plan. My reasoning is:
1) This is a tiny microcap with virtually no open market. This levers price movements.
2) What is released by the co to the public will almost certainly not be the whole story. It is highly likely that at least one of their scientists will be working on at least one early stage antibody which will only be made public if /when at a more advanced stage.
3) The SP will always include a premium for likely buyout. In view of BVXP.s micro-sizing, a major pharma could bid from 'petty cash'.
4) Most UNimportant in these circumstances, you get a dividend from holding them.
5) Buffetology Fund own app 11%, so it fulfils that fund's criteria.
Apart from a lifetime of learning (and not always winning) I do not claim expertise, so please DYOR.
There is a detailed report on Bioventix's recent AGM which can be found in our members area here: https://sharesoc.ning.com/xn/detail/6389471:Comment:55228
To access the report, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: hTTps://www.sharesoc.org/membership/
Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the report (and reports on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: hTTps://www.sharesoc.org/contact-us/
Can't see this falling further without being on the end of a bid. Good luck to all LTHs and please DYOR. Have a happy Xmas.
RE BUFFETTOLOGY FUND - Not to be confused with Warren Buffett's actual funds - quote from hTPp://www.castlefield.com/cfp-sdl-fund-range/cfp-sdl-uk-buffettology-fund/: "The Fund is managed by Keith Ashworth-Lord of Sanford DeLand Asset Management. Keith, is able to draw on 30 years of equity market experience and is a seasoned practitioner of ‘Business Perspective Investing’, as championed by Ben Graham and Warren Buffett. " - so Castlefield are following the principles of Buffett, but not under his direction in any way.
From the RNS, it is the BUFFETTOLOGY FUND - now over 15%
Great that this are in sticky hands and these guys do their homework
Someone seems confident on BVXP's prospects
Wow, someone was prepared to buy £181k worth at £40
Someone is very confident
Article by Phil Oakley of Investors Chronicle on why good companies need growth.
"Bioventix makes antibodies for use in medical testing. In many ways it is an investor’s dream business. It sells its antibodies to medical testing machine companies such as Siemens or Roche. Every time a Bioventix antibody is used in a blood test it receives a royalty. These royalties are small, but with millions of tests done every year they add up to a meaningful amount of money.
The great thing about Bioventix is that it is such a small company, with its products being developed by just a few people working out of a laboratory in Surrey. Virtually all its sales growth over the past five years has fed through to operating profits and has helped to create an exceptionally profitable business.
The investment needed to grow has been minimal with the increase in capital employed almost entirely attributable to the company’s rising cash balance. There are high hopes for its troponin antibody which can reveal if someone has had a heart attack. Competition is a concern from other types of antibody, but growth from new products could see big growth in future profits and cash flows that need little extra investment."
Wonder what is going on - the price was already on the high side but has surged further.
any idea?
The BUFFETTOLOGY FUND has increased their stake to over 14%. Although they don't seem too hot in completing the holdings RNS as there seem to be mistakes in most of the recent ones I have looked at. The percentages are not consistent and the number of shares seems stuck at 5,140674
Hopefully, we get positive news on Troponin revenues.
Just noticed a twitter from Leon Boros about approval for Troponin. As Leon comments this could be massive for BVXP
see https://twitter.com/Boros10/status/1018790692498411520
There is a small mention of bvxp in page 26 of the Master investor Magazine.
"Another top tip is to consider a "picks and shovels" strategy by investing in areas such as diagnostics and biotech/healthcare service providers. These companies will earn money regardless of whether their customers' research is ultimately successful. One particular business doing well in this area is antibody developer Bioventix (LON:BVXP), shares in which have risen from 520p to 2,978p since listing on AIM in April 2014"
Matt, agree at this level it is fully valued and perhaps even overvalued with what we know. Hence, I cannot fault some profit taking. However, BVXP has always surprised in the past and so I am happy to hold as a core holding.
Very tempting.......!!